Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Frontiers in Endocrinology, 2022 The incretin hormone glucagon-like peptide-1 (GLP-1) has received enormous attention during the past three decades as a therapeutic target for the treatment of obesity and type 2 diabetes.
Qiming Tan +7 more
doaj +1 more source
Vitae, 2022 Background: Diabetes mellitus treatment is based on oral hypoglycemic agents or insulin. Medicinal plants constitute an option, and the leaves of Prosopis ruscifolia (Pr) were shown to be effective in reducing glycemia in hyperglycemic animals. Objective:
María Luisa Kennedy +4 more
doaj +1 more source
Genetic variants affecting incretin sensitivity and incretin secretion [PDF]
Diabetologia, 2010 Recent genome-wide association studies identified several novel risk genes for type 2 diabetes. The majority of these type 2 diabetes risk variants confer impaired pancreatic beta cell function. Though the molecular mechanisms by which common genetic variation within these loci affects beta cell function are not completely understood, risk variants may
K, Müssig +4 more
openaire +2 more sources
Comment. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? [PDF]
, 2014 Adam M.
A. M. Deane +6 more
core +1 more source
Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. [PDF]
, 2013 Controversy exists regarding the potential regenerative influences of incretin therapy on pancreatic β-cells versus possible adverse pancreatic proliferative effects.
Atkinson, Mark +5 more
core +2 more sources
Treatment of type 2 diabetes by free fatty acid receptor agonists [PDF]
, 2014 Dietary free fatty acids (FFAs), such as ω-3 fatty acids, regulate metabolic and anti-inflammatory processes, with many of these effects attributed to FFAs interacting with a family of G protein-coupled receptors.
Hudson, Brian D. +3 more
core +2 more sources
Extrapancreatic actions of incretin-based therapies on bone in diabetes mellitus [PDF]
, 2015 Diabetes mellitus is correlated with modifications in bone microarchitectural and mechanical strength, leading to increased bone fragility. The incretin hormones, with a classical effect to increase insulin secretion following food ingestion, are now
Arafat, Mohammad +6 more
core +2 more sources
Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study [PDF]
, 2015 AIMS:Glucagon-like peptide 1 receptor agonists (GLP-1 RA) induce weight loss and reduction in adipose tissue, but the effects of GLP-1 RA on the distribution of fat deposits have been poorly investigated. METHODS: In 25 patients with type 2 diabetes (16
Carnevale, Vincenzo +9 more
core +1 more source
Exposure–Response Analysis of Cardiovascular Outcome Trials With Incretin-Based Therapies
Frontiers in Endocrinology, 2022 Our study aimed to evaluate the exposure–response relationship between incretin-based medications and the risk of major adverse cardiovascular events (MACE) using cardiovascular outcome trials (CVOTs).
Qi Pan, Mingxia Yuan, Lixin Guo
doaj +1 more source
Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes
Journal of Obesity & Metabolic Syndrome, 2021 Type 2 diabetes (T2D) is a multifaceted metabolic disorder associated with distinctive pathophysiological disturbances. One of the pathophysiological risk factors observed in T2D is dysregulation of the incretin hormones, glucose-dependent insulinotropic
Jared Rosenberg +5 more
doaj +1 more source